Helping In The Search For An ALS Treatment
Originally published Fall 1999
C. Scott McLanahan, M.D.

Carolina Neurosurgery & Spine Associates is playing an integral part in an innovative clinical trial to determine the efficacy of new drug, BDNF, in the treatment of Amyotrophic Lateral Sclerosis (ALS). BDNF is a synthetic protein similar to one found naturally in the nervous system. Studies have found that this protein enhances the function of damaged motor neurons. For this clinical trial, BDNF must be administered directly to the motor neurons found in the spinal cord. The intricate task of implanting the pump which delivers BDNF intrathecally into the patient’s cerebrospinal fluid lies with Carolina Neurosurgery & Spine Associates. In fact, the first BDNF pump for this worldwide clinical trial was implanted by practice physician C. Scott McLanahan, M.D., in Charlotte, NC. “We’re pleased to provide neurosurgical support for this groundbreaking effort to identify a promising treatment for ALS,” said Dr. McLanahan.

Carolinas ALS Center is one of only 16 medical facilities around the world, and six within the United States, participating in this three-year study. For more information, contact Carolina Neurosurgery & Spine Associates at 1-800-344-6716
or click here.




Current Issue -Subscribe - Unsubscribe- Article Archive - cnsa.com

© 2002 Carolina Neurosurgery & Spine Associates